Why Wall Street and Jim Cramer think Danaher stock is ‘ready to go for a romp’

Why Wall Street and Jim Cramer think Danaher stock is ‘ready to go for a romp’

Danaher is finally turning the corner. CNBC’s Jim Cramer sees it. Wall Street does, too. The life sciences stock is “ready to go for a romp” after years of “nightmare” performance, Cramer said during Friday’s December Monthly Meeting for Investing Club members. Danaher — which makes tools and technologies used by pharmaceutical, biotech, and medical…

Read More
Zealand Pharma unveils 2030 plan as weight loss competition heats up

Zealand Pharma unveils 2030 plan as weight loss competition heats up

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand…

Read More